FDA Panel Revokes Avastin Breast Cancer Approval

An advisory committee of the Food and Drug Administration (FDA) has voted 6-0 that approval of the drug Avastin as a breast cancer treatment should be revoked. The panel said two key studies on Avastin show it is not effective as a breast cancer treatment and concluded that the risks of the drug outweighed the benefits for this treatment. A final decision on Avastin will be made by Commissioner Margaret Hamburg, but the FDA usually follows the advice of its committees. Avastin is still approved as a treatment for other cancers and that status isn't affected by today's vote.

US Oncology | 10101 Woodloch Forest | The Woodlands, TX 77380

Share
 

LegisLink Today



Health Policy Report - September 26, 2014




The US Oncology Network Get Adobe Reader Terms of Use Contact Us